BETA

Beta Drugs Share Price

 

 

Start SIP in BETA

Start SIP

Performance

  • Low
  • ₹1,578
  • High
  • ₹1,615
  • 52 Week Low
  • ₹1,430
  • 52 Week High
  • ₹2,046
  • Open Price₹1,615
  • Previous Close₹1,578
  • Volume3,029

Investment Returns

  • Over 1 Month -1.65%
  • Over 3 Month -13.32%
  • Over 6 Month -10.91%
  • Over 1 Year -14.32%

Smart Investing Starts Here Start SIP with Beta Drugs for Steady Growth!

Invest Now

Beta Drugs Fundamentals Fundamentals refer to the financial data that companies report on a quarterly or annual basis.

  • P/E Ratio
  • -
  • PEG Ratio
  • -
  • Market Cap Cr
  • 1,605
  • P/B Ratio
  • 7.3
  • Average True Range
  • 69.68
  • EPS
  • 45.36
  • Dividend Yield
  • 0
  • MACD Signal
  • -31.42
  • RSI
  • 43.39
  • MFI
  • 18.89

Beta Drugs Financials

Beta Drugs Technicals

EMA & SMA

Current Price
₹1,590.30
+ 12 (0.76%)
pointer
  • Bearish Moving Average 14
  • Bullish Moving Average 2
  • 20 Day
  • ₹1,619.68
  • 50 Day
  • ₹1,675.80
  • 100 Day
  • ₹1,721.91
  • 200 Day
  • ₹1,734.16

Resistance and Support

1594.4 Pivot Speed
  • R3 1,648.00
  • R2 1,631.50
  • R1 1,610.90
  • S1 1,573.80
  • S2 1,557.30
  • S3 1,536.70

Ratings

Master Rating

EPS Strenth

Price Strength

Buyer Demand

Group Rank

Beta Drugs Ltd. specializes in manufacturing and marketing oncology pharmaceutical products, including injectable and oral formulations. The company operates advanced manufacturing facilities in India, providing high-quality cancer treatment solutions to domestic and international markets.

Beta Drugs has an operating revenue of Rs. 861.66 Cr. on a trailing 12-month basis. An annual revenue growth of 24% is outstanding, Pre-tax margin of 16% is great, ROE of 21% is exceptional. The company has a debt to equity of 64%, which is bit higher. The stock from a technical standpoint is trading below to its key moving averages. It needs to take out these levels and stay above it to make any meaningful move. From an O'Neil Methodology perspective, the stock has an EPS Rank of 69 which is a FAIR score but needs to improve its earnings, a RS Rating of 36 which is POOR indicating the underperformance as compared to other stocks, Buyer Demand at D+ which indicates heavy supply, Group Rank of 74 indicates it belongs to a poor industry group of Medical-Diversified and a Master Score of C is fair but needs to improve. Institutional holding has gone up in the last reported quarter is a positive sign. Overall, the stock has mediocre earnings and technical strength, there are superior stocks in the current market environment.

Disclaimer: This stock analysis report is algorithmically generated for informational purposes only and should not be considered as a buy or sell recommendation.

View More

Beta Drugs Corporate Actions - Bonus, Splits, Dividends

Date Purpose Remarks
2025-11-06 Quarterly Results
2025-05-15 Audited Results
2025-03-27 Others To consider other business matters :- The allotment of 4,80,693 fully paid-up equity shares of the Company of face value of INR 10 each, under Bonus Issue. issue of equity shares in the ratio of 1:20 of Rs. 10/-.
2025-02-05 Issue of Bonus & Others To consider other business matters. issue of equity shares in the ratio of 1:20 of Rs. 10/-.
2024-11-06 Quarterly Results
Date Purpose Remarks
2025-03-26 Bonus Rs.0.00 issue of equity shares in the ratio of 1:20 of Rs. 10/-.

Beta Drugs F&O

Beta Drugs Shareholding Pattern

66.73%
0.9%
21.81%
10.56%

About Beta Drugs

  • NSE Symbol
  • BETA
  • BSE Symbol
  • 531481
  • Chairperson & Managing Director
  • Mr. Rahul Batra
  • ISIN
  • INE351Y01019

Similar Stocks to Beta Drugs

Beta Drugs FAQs

Beta Drugs share price is ₹1,590 As on 26 December, 2025 | 01:17

The Market Cap of Beta Drugs is ₹1605.3 Cr As on 26 December, 2025 | 01:17

The P/E ratio of Beta Drugs is As on 26 December, 2025 | 01:17

The PB ratio of Beta Drugs is 7.3 As on 26 December, 2025 | 01:17

Open Free Demat Account

Be a part of 5paisa community - The first listed discount broker of India.

+91

By proceeding, you agree to all T&C*

footer_form

Disclaimer: Investment in securities market are subject to market risks, read all the related documents carefully before investing. For detailed disclaimer please Click here.

Q2FY23